+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

S

Actively Recruiting

This research aims to evaluate the effectiveness, safety, and tolerability of combining baxdrostat with dapagliflozin compared to dapagliflozin alone in people with chronic kidney disease CKD and high blood pressure. The goal is to reduce the risk of serious kidney problems, heart failure events, or cardiovascular death. This is a phase III, international, multicenter, randomized, double-blind, placebo-controlled, event-driven study focused on treatment outcomes. Participants who do not already use SGLT2 inhibitors will first undergo a 4-week dapagliflozin run-in period. After that, they will be randomly assigned to receive either baxdrostat plus dapagliflozin or placebo plus dapagliflozin. Baxdrostat dosing may start low and be increased if needed. Study visits will occur frequently early on at 2, 4, 8, 16, 34, and 52 weeks post-randomization, then approximately every 4 months. The study will end when a predetermined number of kidney or cardiovascular events occur. During the study, participants will have scheduled visits for assessments including kidney function, heart health, and safety monitoring. If they stop the study treatment early, they will continue on dapagliflozin alone and remain in the trial for follow-up visits. Researchers will measure outcomes such as sustained kidney function decline, kidney failure, heart failure events, cardiovascular death, and all-cause death over up to 37 months. Data collection continues until the study closes, with safety and tolerability closely observed throughout.

Age: 18Years +All GendersPhase 3
771 locations
A

Actively Recruiting

Hepatocellular carcinoma HCC is a common and serious cancer worldwide, often linked to cirrhosis caused by hepatitis B or C viruses and steatotic liver disease. This research focuses on understanding the causes, patient and tumor characteristics, treatments, and outcomes of HCC in adults across various countries in the Middle East and North Africa region, where the disease burden is significant. Differences in healthcare resources and access in these countries affect diagnosis and treatment outcomes. The study collects and reviews existing medical records of adult patients diagnosed with HCC between 2015 and 2023 in the MENA region. It examines details such as patient demographics, tumor features, risk factors, and treatment methods used. This observational study uses secondary data collection without administering any new treatments or interventions. Participants will have their clinical information, laboratory tests, imaging results, and treatment histories analyzed from medical records. The research team will assess outcomes like overall survival and progression-free survival over an eight-year period. Data completeness and follow-up for at least six months are required for inclusion. The study aims to improve understanding of HCC management and outcomes in this region through detailed data review.

All AgesAll Genders
17 locations